Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Plans $425M Notes Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories today said that it intends to raise $425 million through a public senior notes offering.

The firm said the notes would be due 2020, but it has yet to determine the interest rate and other terms.

Bio-Rad said that it intends to use proceeds from the offering, along with its cash on hand, to redeem all $225 million of its outstanding 7.5 percent senior subordinated notes due 2013 and all $200 million of its outstanding 6.125 percent senior subordinated notes due 2014.

Bio-Rad finished its third quarter ended Sept. 30 with $630.6 million in cash and cash equivalents and $107.4 million in short-term investments.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.